Related Experiment Video
Updated: May 21, 2025
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
Published on: June 18, 2015
Low-dose statins restore innate immune response in breast cancer cells via suppression of mutant p53
Zi Wang1, Meina Shi1, Beijia Liu1
1Faculty of Chinese Medicine and State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China.
Background:
Breast cancer's high recurrence and treatment side effects demand safer, more effective therapies. Mutations in the critical TP53 gene, which normally prevents cancer, can instead promote it. This study explores if low-dose statins can curb mutant p53 activation in breast cancer's immune signaling, hindering tumor immune evasion.
Methods:
The study used diverse breast cancer cell lines with varying p53 statuses. Techniques included Western blot, transfection, qRT-PCR, co-immunoprecipitation, nuclear fractionation, and immunohistochemistry. In vivo experiments used BALB/c mice, with bioinformatics analysis via cBioPortal.
Results:
The study found that suppressing mutant p53 restores innate immunity and enhances cancer treatment. Low-dose statins promoted IRF3 nuclear translocation by inhibiting mutant p53. Lovastatin treatment in vivo increased phosphorylated TBK1 and IRF3 levels and induced CD8+ T lymphocyte infiltration in tumors.
Conclusion:
The findings suggest low-dose statins can enhance innate immunity in breast cancer by degrading mutant p53, offering new treatment possibilities. Caution is advised, and further research is needed to address limitations and provide solid evidence for clinical use.
Insights
Low-dose statins may improve breast cancer treatment by inhibiting mutant p53, restoring the immune system
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Breast cancer recurrence and treatment toxicity necessitate novel therapies.
- Mutations in the tumor suppressor TP53 gene can drive cancer progression.
- Investigating mutant p53's role in immune evasion is crucial for therapeutic development.
Purpose of the Study:
- To determine if low-dose statins can inhibit mutant p53 activity in breast cancer.
- To explore the impact of statins on breast cancer immune signaling pathways.
- To assess the potential of statins in overcoming tumor immune evasion.
Main Methods:
- Utilized various breast cancer cell lines with different p53 mutation statuses.
- Employed techniques including Western blot, qRT-PCR, and immunohistochemistry.
- Conducted in vivo studies in mice and analyzed data using cBioPortal.
Main Results:
- Mutant p53 suppression was found to restore innate immunity and improve treatment efficacy.
- Low-dose statins promoted IRF3 nuclear translocation by inhibiting mutant p53.
- In vivo lovastatin treatment increased immune cell infiltration and key signaling molecules.
Conclusions:
- Low-dose statins show potential for enhancing innate immunity in breast cancer via mutant p53 degradation.
- These findings suggest a new therapeutic avenue for breast cancer treatment.
- Further research is required to validate these results for clinical application.
Related Concept Videos
02:23Abnormal Proliferation
01:31The Intrinsic Apoptotic Pathway
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...